5-溴-2-甲基-4-硝基-1H-咪唑 | 18874-52-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-溴-2-甲基-4-硝基-1H-咪唑
• 中文别名: 5-溴-2-甲基-4-硝基咪唑
• 英文名称: 5-bromo-2-methyl-4-nitro-1H-imidazole
• 英文别名: 5(4)-bromo-2-methyl-4(5)-nitroimidazole；2-methyl-4(5)-nitro-5(4)-bromoimidazole；5-bromo-2-methyl-4-nitroimidazole；5-Bromo-2-methyl-4-nitro-1H-imidazole；4-bromo-2-methyl-5-nitro-1H-imidazole
• CAS: 18874-52-7
• 化学式: C₄H₄BrN₃O₂
• mdl: MFCD00464335
• 分子量: 205.999
• InChiKey: YOJYWZSEUWUYAQ-UHFFFAOYSA-N

物化性质

• 熔点：
  225°C (dec.)
• 沸点：
  391.0±22.0 °C(Predicted)
• 密度：
  1.956±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R20/21/22
• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光，惰性气体环境。

SDS

Name:	5-Bromo-2-methyl-4-nitro-1h-imidazole 97% Material Safety Data Sheet
Synonym:
CAS:	18874-52-7

Section 1 - Chemical Product MSDS Name:5-Bromo-2-methyl-4-nitro-1h-imidazole 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18874-52-7	5-Bromo-2-methyl-4-nitro-1H-imidazole	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18874-52-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 225 deg C(decom)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H4BrN3O2
Molecular Weight: 206

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18874-52-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Bromo-2-methyl-4-nitro-1H-imidazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 18874-52-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18874-52-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18874-52-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-甲基-4-硝基-1H-咪唑 在 硫化氢 、 氨 作用下， 生成 2-methyl-5-nitro-3H-imidazole-4-thion; ammonium salt
  参考文献：
  名称：

  Bhagwat; Pyman, Journal of the Chemical Society, 1925, vol. 127, p. 1835

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基-4-硝基咪唑 在 溴 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以93%的产率得到5-溴-2-甲基-4-硝基-1H-咪唑
  参考文献：
  名称：

  5-硝基咪唑系列中的高效微波辅助钯催化的铃木-宫浦交叉偶联反应

  摘要：

  钯催化的Suzuki合成新的简单，快速且高收率的合成方法（平均收率= 83％），合成各种4-芳基，4-杂芳基和4-苯乙烯基-1,2-二甲基-5-硝基-1 H-咪唑描述了使用微波辐射的-Miyaura交叉偶联反应。 交叉偶联-5-硝基咪唑-钯-Suzuki反应-芳基化

  DOI：

  10.1055/s-0029-1216905

文献信息

• 一种氚标记甲硝唑及其制备方法
  申请人：华中农业大学

  公开号：CN106674123B

  公开（公告）日：2019-05-17

  本发明属于放射性同位素标记制备领域，具体涉及一种氚标记甲硝唑及制备方法。以2‑甲基‑5‑硝基咪唑为原料，与N‑碘代丁二酰亚胺反应得到4‑碘‑2‑甲基‑5硝基咪唑，在钯碳催化下，4‑碘‑2‑甲基‑5硝基咪唑与氚气发生氚卤交换，生成4‑3H‑2‑甲基‑5‑硝基咪唑，最后与环氧乙烷反应得到4‑3H‑甲硝唑。合成的产物经制备液相纯化后得到高比活度(22.08Ci/g)、高放化纯度(≥98％)和高化学纯度(≥98％)的4‑3H‑甲硝唑。本发明可作为放射性示踪剂用于甲硝唑在动物体内的吸收、分布、代谢和残留消除研究。
• Synthesis of 4-aroyl-5-nitro-1<i>H</i>-imidazoles and 4-aroyl-5-aminoimidazoles
  作者：J. Donald Albright、Daniel B. Moran

  DOI：10.1002/jhet.5570230350

  日期：1986.5

  reaction of α-(aryl)-4-morpholineacetonitriles (masked aroyl anion equivalents) with N-protected 4(5)-bromo-5(4)-nitro-1H-imidazoles gave 4-aroyl-5-nitroimidazoles which were reduced to afford 4-aroyl-5-aminoimidazoles.

  α-（芳基）-4-吗啉乙腈（掩蔽的芳酰基阴离子当量）与N-保护的4（5）-溴-5（4）-硝基-1 H-咪唑的反应得到4-芳酰基-5-硝基咪唑还原得到4-芳酰基-5-氨基咪唑。
• [EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG<br/>[FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX
  申请人：PHARMINOX LTD

  公开号：WO2012085501A1

  公开（公告）日：2012-06-28

  Compounds of formula (I) and pharmaceutically acceptable salts, hydrates or solvates thereof are provided (I) wherein B, X, and Y are as defined herein. The compounds are of use in methods of regulating cell proliferation, inhibiting cell cycle progression, and/or promoting apoptosis, and in the treatment of proliferative disorders.

  提供具有化学式（I）及其药用可接受的盐、水合物或溶剂化合物（I）的其中B、X和Y的定义如本文所述。这些化合物在调节细胞增殖、抑制细胞周期进展和/或促进凋亡的方法中有用，并用于治疗增生性疾病。
• NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS
  申请人：Leonardi Amedeo

  公开号：US20090042841A1

  公开（公告）日：2009-02-12

  This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

  本发明涉及一种新型杂环化合物，其具有选择性亲和力，适用于代谢型受体mGlu5亚型，以及该类化合物的制药组合物及其在治疗下尿路障碍（例如下尿路神经肌肉功能障碍）、偏头痛和胃食管反流病（GERD）方面的用途。
• Michael-type addition of azoles of broad-scale acidity to methyl acrylate
  作者：Sławomir Boncel、Kinga Saletra、Barbara Hefczyc、Krzysztof Z Walczak

  DOI：10.3762/bjoc.7.24

  日期：——

  An optimisation of Michael-type addition of azole derivatives of broad-scale acidity - ranging from 5.20 to 15.00 pK(a) units - namely 4-nitropyrazole, 3,5-dimethyl-4-nitropyrazole, 4(5)-nitroimidazole, 4,5-diphenylimidazole, 4,5-dicyanoimidazole, 2-methyl-4(5)-nitroimidazole, 5(4)-bromo-2-methyl-4(5)-nitroimidazole and 3-nitro-1,2,4-triazole to methyl acrylate as an acceptor was carried out. The optimisation

  广泛酸度的唑类衍生物的迈克尔型加成优化 - 范围从 5.20 到 15.00 pK(a) 单位 - 即 4-硝基吡唑、3,5-二甲基-4-硝基吡唑、4(5)-硝基咪唑、4 ,5-二苯基咪唑、4,5-二氰基咪唑、2-甲基-4(5)-硝基咪唑、5(4)-溴-2-甲基-4(5)-硝基咪唑和3-硝基-1,2,4-三唑以丙烯酸甲酯为受体进行反应。优化过程涉及使用适当的碱性催化剂（DBU、DIPEA、NaOH、NaH、TEDA）、供体/碱/受体比率和反应温度。反应在作为溶剂的DMF中进行。以中等至极好的产率获得目标迈克尔加合物。重要的是，对于咪唑和 1,2,4-三唑衍生物，没有获得相应的区域异构体。